Healthcare

Algorae Pharmaceuticals Ltd (ASX:1AI) shares fell 5.88% to AUD 0.016 on 2 April 2026, despite the company announcing a key regulatory milestone. The stock, however, remains up 60% over the past six months, indicating strong prior momentum. Today’s decline came even as the company …

The company's business model generates recurringrevenuethrough transaction-based licensing rather than traditional flat-fee software arrangements. This approach aligns revenue growth with underlying imaging volumes and clinical utilisation, creating natural scalability characteristics. Pro Medicus' recent share buyback announcement reflects management confidence in the company's strategic positioning …

Neurizon Therapeutics Ltd (ASX:NUZ) shares rose 4% to AUD 0.078 on 1 April 2026 after the company released new preclinical data for its lead drug candidate, NUZ-001. Despite today’s gain, the stock remains down approximately 35% over the past year, with the latest update …

AdAlta Ltd (ASX:1AD) shares closed flat at AUD 0.0040 on 1 April 2026, despite touching an intraday high of AUD 0.0050. The steady close followed the release of a clinical update highlighting encouraging outcomes from ongoing trials of its investigational cancer therapy, BZDS1901.

Arovella Therapeutics Ltd (ASX:ALA) shares closed unchanged at AUD 0.070 on 1 April 2026, after reaching an intraday high of AUD 0.073 during the morning session. The muted closing performance comes despite the company releasing encouraging early-stage data demonstrating the effectiveness of its cancer-targeting …

Bioxyne Limited (ASX:BXN) shares edged up 1.59% to AUD 0.064 on 1 April 2026. The move coincided with the announcement that its wholly owned subsidiary, Breathe Life Sciences (BLS), has entered into a major international manufacturing agreement with Canadian-based giant Aurora Cannabis. The stock …

Actinogen Medical Ltd shares (ASX:ACW) climbed 8.82% to AUD 0.037 during the afternoon session on 1 April 2026, with the stock now up 23.33% over the past year. Today’s upward movement followed the company’s announcement that it has initiated the open-label extension phase of …